Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.35 |
| ▸ | PGK2 | P07205 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14570493 | 0.86 | IDO1 (0.43) | IDO1RAPGEF4GRIN2BNOS1NOS3 | |
| SCHEMBL16767879 | 0.84 | GRIN2B (0.44) | IDO1RAPGEF4GRIN2BNOS1NOS3 | |
| SCHEMBL12807082 | 0.84 | RXRA (0.39) | IDO1RAPGEF4GRIN2BNOS1NOS3 | |
| SCHEMBL5776968 | 0.84 | IDO1 (0.54) | IDO1DAOTACR1TAAR1 | |
| SCHEMBL15704675 | 0.83 | RXRA (0.39) | IDO1RAPGEF4NOS1NOS3NOTUM | |
| SCHEMBL799008 | 0.83 | IDO1 (0.41) | IDO1RAPGEF4GRIN2BNOS1NOS3 | |
| SCHEMBL799344 | 0.81 | RXRA (0.45) | IDO1RAPGEF4GRIN2BNOS1NOS3 | |
| SCHEMBL823297 | 0.81 | IDO1 (0.44) | IDO1RAPGEF4GRIN2BNOS1NOS3 | |
| SCHEMBL799078 | 0.81 | IDO1 (0.39) | IDO1RAPGEF4GRIN2BNOS1NOS3 | |
| SCHEMBL12765145 | 0.79 | NOS1 (0.43) | IDO1RAPGEF4GRIN2BNOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137430-A1 | Nuclear Transport Modulators And Uses Thereof | KARYOPHARM THERAPEUTICS INC (US) | 2017-05-18 | — | — | US | disclosed |
| US-20160355475-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20160320397-A1 | USE OF BUBR1 AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2016-11-03 | — | — | US | disclosed |
| US-9428490-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9272987-B2 | Diazeniumdiolate cyclohexyl derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9181245-B2 | Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease | Janssen Pharmaceuticals, Inc. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150307496-A1 | NOVEL TRICYCLIC 3,4-DIHYDRO-2H-PYRIDO[1,2-a]PYRAZINE-1,6-DIONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-29 | — | — | US | disclosed |
| US-9108920-B2 | Diazeniumdiolate heterocyclic derivatives | MERCK SHARP & DOHME CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150141411-A1 | SUBSTITUTED 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | CELLZOME LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| US-9029377-B2 | Platelet-activating factor receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-05-12 | — | — | US | disclosed |
| US-7615300-B2 | Development of novel proton-conductive polymers for proton exchange membrane fuel cell (PEMFC) technology | The Board of Regents University and Community College System of Nevada on Behalf of the University of Nevada (US) | 2009-11-10 | — | — | US | disclosed |
| US-7592366-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20090186874-A1 | Carboxamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| US-7468440-B2 | Malonamides and malonamide derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080300269-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
| WO-2007070173-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1790636-A1 | PIPERIDINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-05-30 | — | — | EP | disclosed |
| US-20070048579-A1 | Development of novel proton-conductive polymers for proton exchange membrane fuel cell (PEMFC) technology | Board of Regents University and Community College System of Nevada | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300269-A1 | THERAPEUTIC COMPOUNDS | THPO, HLA-C, PIGO | IDO1 3102/4885RAPGEF4 3696/4885GRIN2B 3382/4885 |
| US-20170137430-A1 | Nuclear Transport Modulators And Uses Thereof | XPO1, XPO5, XPOT | IDO1 4080/4885RAPGEF4 1337/4885GRIN2B 2896/4885 |
| US-20090186874-A1 | Carboxamide derivative and use thereof | NTSR2, NTSR1, CNR2 | IDO1 623/4885RAPGEF4 3806/4885GRIN2B 243/4885 |
| US-20150141411-A1 | SUBSTITUTED 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | BACE1, PSEN1, BACE2 | IDO1 550/4885RAPGEF4 3524/4885GRIN2B 277/4885 |
| US-20160355475-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC2, HDAC1, HDAC3 | IDO1 13/4885RAPGEF4 2870/4885GRIN2B 719/4885 |
| US-20150307496-A1 | NOVEL TRICYCLIC 3,4-DIHYDRO-2H-PYRIDO[1,2-a]PYRAZINE-1,6-DIONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | IDO1 2335/4885RAPGEF4 2644/4885GRIN2B 95/4885 |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, COXFA4L2 | IDO1 4129/4885RAPGEF4 3560/4885GRIN2B 1471/4885 |
| US-20160320397-A1 | USE OF BUBR1 AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BUB1B, BUB1, BUB3 | IDO1 2495/4885RAPGEF4 2565/4885GRIN2B 4394/4885 |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | IDO1 288/4885RAPGEF4 3887/4885GRIN2B 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.